Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer

ABSTRACT: This phase II study will evaluate the efficacy of the combination of two monoclonal antibodies (Avastin + Erbitux) with irinotecan, in patients with colorectal cancer progressed after 1st line treatment with FOLFIRI Avastin or XELIRI Avastin.

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2055691 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR